InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,570.64
(
-0.89%
)
US TECH 100
19,045.60
(
-1.32%
)
Dow Jones
40,712.78
(
-0.43%
)
Brent Oil
76.75
(
0.20%
)
Bitcoin
60,640.44
(
0.44%
)
Post# of 252959
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

biomaven0

Send PM Follow Ignore
Followers 82
Posts 4778
Boards Moderated 0
Alias Born 02/27/2007

biomaven0

Re: mcbio post# 119059

Friday, 04/29/2011 1:16:37 PM

Friday, April 29, 2011 1:16:37 PM

Post# of 252959
I agree with jq1234 that Nexavar has been remarkably consistent across trials in PFS. In addition this trial is a homogeneous group of patients.

So I also take this as bullish for Aveo - I think this is a distinctly unappreciated stock as I believe it is going to be the drug of choice for VEGF combo therapy.

Peter
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up